Suggests autoimmune hepatitis.
Simplified AIH Score Calculator
Answer the following questions to calculate the AIH score:
(2 points if Gamma Globulin greater than or equal to 2.0 g/dL or IgG greater than or equal to 20 g/L or greater than or equal to 2x ULN; otherwise 0 points)
Autoimmune Hepatitis: A Comprehensive Overview
1. Introduction
Autoimmune hepatitis (AIH) is a chronic, progressive inflammatory liver disease of unknown etiology characterized by loss of immune tolerance to hepatocytes, leading to interface hepatitis (piecemeal necrosis), fibrosis, and potentially cirrhosis if left untreated. It can present acutely, rapidly progress to fulminant hepatic failure, or manifest insidiously with nonspecific symptoms such as fatigue, jaundice, arthralgia, and amenorrhea. AIH predominantly affects females (female-to-male ratio ~4:1), with peak onset in two age groups: adolescents and young adults (10–30 years) and middle-aged individuals (45–70 years). With timely diagnosis and immunosuppressive therapy, most patients achieve remission and have near-normal life expectancy.
2. Epidemiology & Demographics
- Incidence: ~1–2 cases per 100,000 per year in Western countries; higher in Scandinavia and the UK (~2.4/100,000).
- Prevalence: Estimated at 10–20 cases per 100,000.
- Gender: Female predominance (70–80% of cases).
- Ethnicity: More common in White populations; emerging reports suggest increasing recognition among Asian and Black individuals.
3. Pathogenesis
The exact etiology remains elusive, but AIH arises from a complex interplay of genetic susceptibility, environmental triggers, and immune dysregulation:
Genetic Factors
- Strong association with HLA class II alleles:
- HLA-DRB103:01 (linked to earlier onset, more severe disease, extrahepatic manifestations)
- HLA-DRB104:01 (associated with later-onset AIH and overlapping features)
- Non-HLA genes: STAT4, SH2B3, CARD10, TNF-α, and IL10 polymorphisms.
Environmental Triggers
- Viral infections (e.g., measles, hepatitis viruses, EBV, SARS-CoV-2) may initiate molecular mimicry.
- Drugs (e.g., minocycline, nitrofurantoin, statins) can induce drug-induced autoimmune hepatitis-like syndromes.
Immune Mechanisms
- Loss of tolerance leads to CD4⁺ T-cell–mediated hepatocyte injury.
- Autoantibodies (ANA, SMA, anti-LC1, anti-SLA/LP) serve as markers but are not directly pathogenic.
- Regulatory T cell (Treg) dysfunction and aberrant B-cell activation contribute.
4. Clinical Features
Symptoms
- Asymptomatic (30–50% identified incidentally via abnormal LFTs)
- Fatigue (70–80%)
- Jaundice (50–60%)
- Abdominal pain, nausea, anorexia
- Arthralgia/myalgia (30–40%)
- Amenorrhea, skin rashes (e.g., vitiligo, alopecia)
Severe Presentations
- Acute hepatitis with massive necrosis → fulminant liver failure (5–10% of cases)
- Cirrhosis at diagnosis (20–30%)
Physical Signs
- Hepatomegaly
- Splenomegaly
- Ascites, jaundice, spider angiomata, palmar erythema (suggestive of advanced disease)
5. Laboratory & Serological Features
| Parameter | Typical Findings |
|---|---|
| Liver enzymes | ↑ AST/ALT (often >5× ULN; ALT may be higher than ALP) ↑ Bilirubin (especially direct) ↓ Albumin, prolonged PT in severe cases |
| Immunoglobulins | ↑ IgG (>1.1 × ULN); IgA may also be elevated |
| Autoantibodies | • ANA (antinuclear antibodies): 50–80% • SMA (smooth muscle antibodies): 30–60% • Anti-LC1 (liver–kidney microsomal type 1): 10–20% (more common in children) • Anti-SLA/LP (soluble liver antigen/liver pancreas): 10–30%; highly specific for AIH |
| Viral serologies | Negative for HAV, HBV, HCV, HIV, EBV, CMV |
Note: Seronegative AIH (no classic autoantibodies) accounts for ~10% of cases; diagnosis relies on histology and exclusion of other causes.
6. Histopathological Features (Liver Biopsy)
- Interface hepatitis: Lymphoplasmacytic infiltration at portal–parenchymal interface with hepatocyte damage (piecemeal necrosis).
- Lobular inflammation: Spotty necrosis, rosette formation.
- Fibrosis/cirrhosis in advanced disease.
Key differentiator from other liver diseases: Absence of bile duct injury (helps distinguish from PBC), cholestasis (vs. PSC), or steatosis (vs. NAFLD).
7. Diagnosis
AIH diagnosis requires a high index of suspicion and integration of clinical, laboratory, serological, histological, and exclusion data. The International Autoimmune Hepatitis Group (IAIHG) developed the simplified AIH Score (2008), widely used in clinical practice and trials.
8. Simplified AIH Scoring System (IAIHG, 2008)
| Parameter | Points |
|---|---|
| ANA and/or SMA | 1:1:40 or higher = 1 point1:80 or higher = 3 points |
| Anti-LC1 positivity | 2 points |
| IgG level | > upper limit of normal (ULN) to ≤1.5× ULN = 1 point>1.5× ULN = 3 points |
| Liver histology | Suggestive (interface hepatitis, spotty necrosis, rosettes) = 2 pointsDefinitive (interface hepatitis + plasma cells + lobular disarray) = 4 points |
| Other autoimmune diseases | 2 points (e.g., thyroiditis, RA, UC, T1DM) |
| Viral serology & imaging | Negative for viral hepatitis and structural liver disease = 2 points |
Scoring Interpretation
| Total Score | Diagnostic Probability |
|---|---|
| ≤5 | Unlikely AIH |
| 6–7 | Possible AIH (consider other etiologies; may trial immunosuppression if high suspicion) |
| ≥8 | Probable/Definite AIH |
Note: Histology is essential—without it, maximum score = 9. A score of ≥7 with histological confirmation is generally considered diagnostic.
Clinical Pearl: The simplified score does not require HLA typing or liver biopsy in all cases (though biopsy remains recommended), and it allows scoring without considering treatment response—a major advantage over the original 1999 score.
9. Differential Diagnosis
| Disease | Key Distinguishing Features |
|---|---|
| Chronic viral hepatitis (B/C) | Positive serology; no autoantibodies/IgG elevation |
| Drug-induced liver injury (DILI) | Temporal association with drug exposure; often resolves after discontinuation |
| Non-alcoholic fatty liver disease (NAFLD/NASH) | Steatosis on histology; metabolic risk factors; no autoantibodies |
| Primary biliary cholangitis (PBC) | AMA positivity; cholestatic pattern (↑ ALP > ALT); antimitochondrial antibodies |
| Primary sclerosing cholangitis (PSC) | Beaded bile ducts on ERCP/MRCP; associated with IBD |
| Alcoholic hepatitis | History of heavy alcohol use; elevated GGT; AST:ALT >2 |
10. Classification
Type 1 AIH
- Most common (~80% of cases)
- Autoantibodies: ANA and/or SMA ± anti-LC1
- Associated with HLA-DR3/DR4
- Overlaps with other autoimmune diseases (e.g., UC, thyroiditis)
Type 2 AIH
- Less common (<20%, more frequent in children)
- Autoantibodies: Anti-LC1 and/or anti-SLAs (ANA/SMA typically negative)
- Strongly associated with HLA-DR7 and DRB1*03:01
- Often more aggressive, higher relapse rates
11. Treatment
Indications for Treatment
- Active hepatitis with symptoms or elevated transaminases (ALT/AST >2× ULN) and ↑ IgG or histologically active disease.
Asymptomatic patients with mild enzyme elevation and no fibrosis may be monitored, but most require treatment.
First-Line Therapy
Standard regimen: Prednisone (or prednisolone) + Azathioprine
| Agent | Dosing |
|---|---|
| Prednisone | Start 0.5–1 mg/kg/day (max 40–60 mg/day), taper over 4–8 weeks to 10–15 mg/day maintenance |
| Azathioprine | 50–100 mg/day (adjusted for TPMT activity; target dose 1–2 mg/kg/day) |
Alternative: Monotherapy with prednisone if azathioprine contraindicated (e.g., TPMT deficiency, pancreatitis, bone marrow suppression).
Treatment-Free Remission
- Achieved in ~20–30% of patients after minimum 2 years of therapy.
- More likely in patients with:
- Histological remission (no interface hepatitis)
- Normal IgG and transaminases for ≥1 year
- Absence of cirrhosis
- Relapse occurs in >80% of patients upon withdrawal if criteria not met.
Relapse Management
- Reinitiate previous regimen or intensify therapy.
- Consider switching azathioprine to mycophenolate mofetil (MMF) if intolerant.
Second-Line Agents
- Mycophenolate mofetil (MMF): 1–1.5 g BID (preferred for azathioprine intolerance, bone marrow suppression, or pregnancy).
- Calcineurin inhibitors: Tacrolimus or cyclosporine (for refractory disease).
- Biologics: Rituximab, infliximab (reserved for rescue therapy in clinical trials).
Liver Transplantation
- Indicated for acute liver failure unresponsive to medical therapy, or decompensated cirrhosis (MELD >15).
- 5-year survival: >80%; recurrence rate ~10–20% (often mild, responsive to treatment).
12. Prognosis
| Outcome | Details |
|---|---|
| Response to therapy | 80–90% achieve remission within 2 years |
| 5-year survival | >90% with treatment vs. ~50% without |
| Cirrhosis at diagnosis | 30–40%; accelerated progression if untreated |
| Risk of HCC | Elevated in AIH-related cirrhosis (annual risk ~1–2%) |
13. Special Considerations
Pregnancy
- Safe to conceive in remission; flares occur in 20–40% postpartum.
- Azathioprine and prednisone are safe during pregnancy (FDA Category D but benefits outweigh risks).
- Avoid MMF (teratogenic).
Overlap Syndromes
- AIH–PBC overlap: ANA/SMA + AMA positivity; mixed histology.
- AIH–PSC overlap: Cholangiographic abnormalities + interface hepatitis.
14. Future Directions
- Biomarker discovery: Serum microRNAs, keratin 18 fragments (M30), and B-cell subsets for monitoring disease activity.
- Novel therapeutics: Targeted immunomodulators (e.g., anti-CD20, IL-6 inhibitors, CAR-Treg therapy).
- Microbiome research: Dysbiosis may modulate immune responses in AIH.
References
- Czaja AJ, Mackay IR, Bailie MW, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):316–325. doi:10.1002/hep.22319
- European Association for the Study of the Liver (EASL). EASL clinical practice guidelines: management of autoimmune hepatitis. J Hepatol. 2022;77(4):1365–1383. doi:10.1016/j.jhep.2022.06.011
- Czaja AJ, Makowiec M, Sawicki A, et al. Diagnosis of autoimmune hepatitis: a comparative study of the 1999 International Diagnostic Score and the simplified scoring system. Am J Gastroenterol. 2010;105(8):1843–1852. doi:10.1038/ajg.2010.75
- Vierling JM, Fontana RJ, Davern TJ, et al. The natural history of autoimmune hepatitis in the United States: a population-based study. Hepatology. 2021;73(3):1142–1154. doi:10.1002/hep.31568
- Krawitt ME, Fox PS, Hoyer TF, et al. Autoimmune hepatitis: clinical course and outcome in 100 patients. Ann Intern Med. 2004;140(1):1–9. doi:10.7326/0003-4819-140-1-200401060-00005
- Papatheodoridis GV, Dalekos GN. Autoimmune hepatitis: from diagnosis to treatment. World J Gastroenterol. 2012;18(39):5477–5487. doi:10.3748/wjg.v18.i39.5477
- European Liver Patients’ Union (ELPU). Autoimmune Hepatitis: A Patient’s Guide. 2nd ed. Brussels, Belgium; 2020. https://elpu.org/wp-content/uploads/2020/11/AIH-Patient-Guide-2020.pdf
- American Association for the Study of Liver Diseases (AASLD). AASLD Practice Guidelines: Autoimmune Hepatitis. Hepatology. 2023 (in press).
Disclaimer
This article is for informational purposes only and does not substitute professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for individual patient management.
Keywords: autoimmune hepatitis, simplified AIH score, ANA, SMA, anti-LC1, IgG, immunosuppression, prednisone, azathioprine, histology, IAIHG.
